Ribavirin Treatment for Severe Schizophrenia with Anti-Borna Disease Virus 1 Antibodies 30 Years after Onset.
Journal
Case reports in psychiatry
ISSN: 2090-682X
Titre abrégé: Case Rep Psychiatry
Pays: United States
ID NLM: 101583308
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
10
2022
revised:
23
12
2022
accepted:
11
02
2023
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
10
3
2023
Statut:
epublish
Résumé
Borna disease virus 1 (BoDV-1) was proven to cause fatal encephalitis in humans in 2018. However, the effects of persistent infections remain unclear. Here, we present the case of a 50-year-old woman with a 30-year history of severe schizophrenia, who was exposed to fleas from stray cats prior to disease onset, suggesting the possibility of zoonosis including BoDV-1 infection. The patient had experienced significant social impairment, thought deterioration, delusions, and hallucinations for more than 20 years. A radioligand assay was used to test the patient for IgG and IgM antibodies against BoDV-1 nucleoprotein (N) and phosphoprotein (P). Based on the protocol for hepatitis C, we treated the patient with 400 mg/day ribavirin, which was later increased to 600 mg/day. The serological examination revealed anti-BoDV-1 N IgG. Although only subtle changes were observed over the 24 weeks of treatment, the family noticed that the patient's Cotard delusions had disappeared 7 months after completing the treatment, accompanied by some improvements in the relationship with the family. Though definite proof was not obtained, this presumed suppression of BoDV-1 by ribavirin leading to improvements in Cotard syndrome-like symptoms suggests that intractable schizophrenia might be one of the BoDV-1 infection phenotypes. Further studies are needed to clarify the effect of persistent BoDV-1 infections in humans.
Identifiants
pubmed: 36891160
doi: 10.1155/2023/4899364
pmc: PMC9988380
doi:
Types de publication
Case Reports
Langues
eng
Pagination
4899364Informations de copyright
Copyright © 2023 Hidenori Matsunaga et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this article.
Références
Brain. 2017 Feb;140(2):497-507
pubmed: 28082298
J Viral Hepat. 2004 Jan;11(1):84-7
pubmed: 14738562
Schizophr Bull. 1995;21(2):167-71
pubmed: 7631163
Jpn J Infect Dis. 2018 Sep 21;71(5):338-342
pubmed: 29848841
Arch Virol. 1998;143(10):2039-44
pubmed: 9856091
J Gen Virol. 2013 Feb;94(Pt 2):247-262
pubmed: 23223618
Schizophr Res. 2012 Apr;136(1-3):128-36
pubmed: 22104141
N Engl J Med. 2018 Oct 4;379(14):1375-1377
pubmed: 30281979
Viruses. 2021 Feb 23;13(2):
pubmed: 33672213
Biol Psychiatry. 2014 Feb 15;75(4):276-83
pubmed: 24199664
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8969-74
pubmed: 12857949
J Virol. 1987 Nov;61(11):3431-40
pubmed: 2444715
N Engl J Med. 2018 Oct 4;379(14):1377-1379
pubmed: 30281984
Transl Psychiatry. 2016 Dec 13;6(12):e982
pubmed: 27959331
J Clin Virol. 2008 Nov;43(3):317-22
pubmed: 18786855
Arch Gen Psychiatry. 1985 Nov;42(11):1093-6
pubmed: 3931604
Front Immunol. 2018 Oct 10;9:2230
pubmed: 30364161
Psychiatry Clin Neurosci. 2010 Jun;64(3):255-61
pubmed: 20408992
Schizophr Bull. 2007 May;33(3):729-36
pubmed: 17085743
Med Microbiol Immunol. 1988;177(2):51-68
pubmed: 2452338
Clin Diagn Lab Immunol. 2005 May;12(5):671-6
pubmed: 15879032
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Antimicrob Agents Chemother. 2002 Jul;46(7):2287-91
pubmed: 12069992
Eur Psychiatry. 1995;10(5):250-8
pubmed: 19698348
Asian J Psychiatr. 2018 Apr;34:67-73
pubmed: 29660614
Mol Psychiatry. 2016 Aug;21(8):1090-8
pubmed: 26194183
Curr Top Microbiol Immunol. 2001;253:157-77
pubmed: 11417134
Genes (Basel). 2022 Jun 18;13(6):
pubmed: 35741850
Vet J. 2014 Aug;201(2):142-9
pubmed: 24480411
Antiviral Res. 2008 Dec;80(3):380-4
pubmed: 18778737